Skip to main content

MFI for Particle Characterization of Biopharmaceuticals Today


Regulatory agencies currently require sub-visible particles to be well characterized in biopharmaceutical formulations due to concerns about undesired side effects and reduced efficacy. Because of this, sub-visible particle characterization is a key step in evaluating the quality attributes of complex biopharmaceuticals. Read this white paper to see how MFI is used for particle characterize in the biopharmaceutical industry. 

Default Literature Icon